Safety, Tolerability and Effect of Laquinimod in Subjects With Relapsing Multiple Sclerosis

- Relapsing Multiple Sclerosis
- Terminated

Study Title: A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis

Teva Identifier: MS-LAQ-302E | 2009-015815-42

ClinicalTrials.gov Identifier: NCT01047319

Study Status: Terminated

Trial Condition(s): Relapsing Multiple Sclerosis

Interventions: Drug: Laquinimod

Study Description

Please refer to ClinicalTrials.gov for a description of the trial

Participation criteria and map of study locations

Key Participation Requirements

Gender: Female, Male

Age Range: Child, Adult, Older Adult

Trial Duration: May 27, 2010 - June 30, 2017

Phase: Phase 3

Study Type

Interventional